Antibiotic Selection Pressure and Resistance in Streptococcus pneumoniae and Streptococcus pyogenes

We correlated outpatient antibiotic use with prevalence of penicillin-nonsusceptible Streptococcus pneumoniae (PNSP), macrolide-resistant S. pneumoniae (MRSP), and macrolide-resistant S. pyogenes (MRGAS) in 20 countries. Total antibiotic use was correlated with PNSP (r = 0.75; p < 0.001), as was macrolide use with MRSP (r = 0.88; p < 0.001) and MRGAS (r = 0.71; p = 0.004). Streptococcal resistance is directly associated with antibiotic selection pressure on a national level.

[1]  D. Livermore.  Bacterial resistance: origins, epidemiology, and impact. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  M. Jones,et al.  Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998. , 1999, The Journal of antimicrobial chemotherapy.

[3]  Y. Carmeli,et al.  Parallel analysis of individual and aggregated data on antibiotic exposure and resistance in gram-negative bacilli. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  F. Baquero,et al.  Streptococcus pyogenes resistance to erythromycin in relation to macrolide consumption in Spain (1986-1997). , 2000, The Journal of antimicrobial chemotherapy.

[5]  J. Mcgowan,et al.  Antimicrobial resistance in hospital organisms and its relation to antibiotic use. , 1983, Reviews of infectious diseases.

[6]  M. Lipsitch,et al.  Measuring and interpreting associations between antibiotic use and penicillin resistance in Streptococcus pneumoniae. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  M. Lipsitch,et al.  Antimicrobial Use and Antimicrobial Resistance: A Population Perspective , 2002, Emerging Infectious Diseases.

[8]  T. Bergan.  Antibiotic usage in Nordic countries. , 2001, International journal of antimicrobial agents.

[9]  W. Goettsch,et al.  Antibiotic use and resistance of Streptococcus pneumoniae in The Netherlands during the period 1994-1999. , 2001, The Journal of antimicrobial chemotherapy.

[10]  O. Cars,et al.  A European study on the relationship between antimicrobial use and antimicrobial resistance. , 2002, Emerging infectious diseases.

[11]  B. Kristiansen,et al.  The prevalence of antibiotic resistance in bacterial respiratory pathogens from Norway is low. , 2001, Clinical Microbiology and Infection.

[12]  M. Pfaller,et al.  Macrolide and Fluoroquinolone (Levofloxacin) Resistances amongStreptococcus pneumoniae Strains: Significant Trends from the SENTRY Antimicrobial Surveillance Program (North America, 1997–1999) , 2000, Journal of Clinical Microbiology.

[13]  A. Marchese,et al.  The evolving threat of antibiotic resistance in Europe: new data from the Alexander Project. , 2000, The Journal of antimicrobial chemotherapy.

[14]  P. Huovinen.  Macrolide-resistant group a streptococcus--now in the United States. , 2002, The New England journal of medicine.

[15]  D E Low,et al.  Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. , 1999, The New England journal of medicine.

[16]  A. Tomasz,et al.  Diversity of penicillin-nonsusceptible Streptococcus pneumoniae circulating in Iceland after the introduction of penicillin-resistant clone Spain(6B)-2. , 2002, The Journal of infectious diseases.

[17]  D. Preston,et al.  Assessment of the Susceptibility of Streptococcus pneumoniae to Cefaclor and Loracarbef in 13 Countries , 2000, Journal of chemotherapy.

[18]  H. Konradsen,et al.  Invasive Pneumococcal Infections in Denmark from 1995 to 1999: Epidemiology, Serotypes, and Resistance , 2002, Clinical and Vaccine Immunology.

[19]  Marc Lipsitch,et al.  Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States , 2003, Nature Medicine.

[20]  R. Herings,et al.  Application of the ATC/DDD methodology to monitor antibiotic drug use , 2005, European Journal of Clinical Microbiology and Infectious Diseases.

[21]  Y. Hirakata,et al.  Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and compatative in vitro activity of the ketolide, telithromycin. , 2002, The Journal of antimicrobial chemotherapy.

[22]  O. Cars,et al.  Variation in antibiotic use in the European Union , 2001, The Lancet.

[23]  P Huovinen,et al.  The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. , 1997, The New England journal of medicine.

[24]  H. Goossens,et al.  Macrolide resistance and erythromycin resistance determinants among Belgian Streptococcus pyogenes and Streptococcus pneumoniae isolates. , 2000, The Journal of antimicrobial chemotherapy.

[25]  K. Seme,et al.  The relationship between trends in macrolide use and resistance to macrolides of common respiratory pathogens. , 2001, The Journal of antimicrobial chemotherapy.

[26]  C. Brun-Buisson,et al.  Outpatient Antibiotic Use and Prevalence of Antibiotic-Resistant Pneumococci in France and Germany: A Sociocultural Perspective , 2002, Emerging infectious diseases.

[27]  A. Ortqvist.  Pneumococcal disease in Sweden: experiences and current situation. , 1999, The American journal of medicine.

[28]  D. Monnet.  Consommation d’antibiotiques et résistance bactérienne* , 2000 .

[29]  M. Čižman,et al.  Antimicrobial resistance of invasive Streptococcus pneumoniae in Slovenia from 1997 to 2000. , 2002, The Journal of antimicrobial chemotherapy.

[30]  F. Baquero,et al.  Antimicrobial Susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenesIsolates and Their Ecological Relationships: Results of a 1-Year (1998–1999) Multicenter Surveillance Study in Spain , 2001, Antimicrobial Agents and Chemotherapy.

[31]  F. Baquero,et al.  Antimicrobial resistance amongst isolates of Streptococcus pyogenes and Staphylococcus aureus in the PROTEKT antimicrobial surveillance programme during 1999-2000. , 2002, The Journal of antimicrobial chemotherapy.

[32]  A. Marchese,et al.  Resistance patterns of lower respiratory tract pathogens in Europe. , 2000, International journal of antimicrobial agents.

[33]  D. Goldmann,et al.  Control of multiply resistant cocci: do international comparisons help? , 2001, The Lancet. Infectious diseases.

[34]  T. Klaukka,et al.  Macrolide-resistant Streptococcus pneumoniae and use of antimicrobial agents. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  J. Primrose,et al.  Antibiotic use in the Australian community, 1990‐1995 , 1997, The Medical journal of Australia.

[36]  M. Jones,et al.  Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in Asia and Europe, 1997-1998. , 2000, The Journal of antimicrobial chemotherapy.

[37]  D. Felmingham,et al.  The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. , 2000, The Journal of antimicrobial chemotherapy.